Table 5 Logistic regression analysis of factors influencing recurrence at therapy cessation
Characteristics | Univariate model | Multivariate model | ||
|---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | |
Male gender | 1.35 (0.45–4.04) | 0.595 | ||
Age | 0.99 (0.94–1.06) | 0.955 | ||
Baseline HBsAg level | 0.99 (0.99–1.02) | 0.966 | ||
Treatment time | 1.01 (0.99–1.03) | 0.340 | ||
Consolidation time | 0.96 (0.91–1.01) | 0.097 | ||
Anti-HBs positive | 0.18 (0.05–0.61) | 0.006 | 0.20 (0.05–0.75) | 0.017 |
IHC with PEG-IFN-α-2b monotherapy | 1.00 | |||
CHB with PEG-IFN-α-2b add-on ETV therapy | 0.30 (0.08–1.12) | 0.073 | ||
CHB with PEG-IFN-α-2b add-on TDF therapy | 0.62 (0.14–2.72) | 0.522 | ||
CHB with PEG-IFN-α-2b add-on TAF therapy | 0.58 (0.06–5.69) | 0.636 | ||
CHB with PEG-IFN-α-2b add-on TMF therapy | < 0.01 | 0.999 | ||
Blood routine test | ||||
White blood cells | 1.07 (0.74–1.54) | 0.720 | ||
Neutrophils | 0.95 (0.58–1.54) | 0.824 | ||
Platelets | 1.01 (1.00-1.02) | 0.012 | 1.01 (1.00-1.02) | 0.049 |
Red blood cells | 0.85 (0.34–2.09) | 0.716 | ||
Hemoglobin | 0.99 (0.97–1.02) | 0.707 | ||
Liver function | ||||
ALT | 1.00 (0.10–1.01) | 0.365 | ||
AST | 1.00 (0.99–1.01) | 0.859 | ||
T-BIL | 0.99 (0.92–1.08) | 0.923 | ||
Total protein | 1.15 (0.99–1.13) | 0.071 | ||
Albumin | 0.97 (0.82–1.11) | 0.711 | ||
Globulin | 1.18 (1.01–1.37) | 0.033 | 1.20 (1.02–1.42) | 0.031 |